Vasant Narasimhan - Novartis Chief Officer
| NOVN Stock | CHF 93.27 0.11 0.12% |
Insider
Vasant Narasimhan is Chief Officer of Novartis AG
| Age | 47 |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alison Martin | Zurich Insurance Group | 49 | |
| Laurent Freixe | Nestl SA | 61 | |
| MBA MBA | Nestl SA | 54 | |
| Mark Senkevics | Swiss Re AG | N/A | |
| Christian Bluhm | UBS Group AG | 54 | |
| Hermann Geiger | Swiss Re AG | 60 | |
| Ulf Schneider | Nestl SA | 58 | |
| Kian Koh | UBS Group AG | 63 | |
| Cristina Wilbur | Roche Holding AG | 56 | |
| Pascale Schmidt | Roche Holding AG | 50 | |
| Guido Furer | Swiss Re AG | 60 | |
| MBA BS | Zurich Insurance Group | 53 | |
| Magdi Batato | Nestl SA | 64 | |
| BA MPP | Swiss Re AG | 62 | |
| Elena Logutenkova | Swiss Re AG | N/A | |
| Stefan Palzer | Nestl SA | 54 | |
| Claudia Bockstiegel | Roche Holding AG | 59 | |
| Cathy Desquesses | Swiss Re AG | 50 | |
| Robert Karofsky | UBS Group AG | 56 | |
| David Rennie | Nestl SA | 57 | |
| Markus Ronner | UBS Group AG | 58 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor, Chief Sandoz | ||
| Steffen Lang, Pres Operations | ||
| MarieFrance Tschudin, Pres Officer | ||
| Paul Penepent, Head Accounting | ||
| Samir MD, Global Relations | ||
| Robert PharmD, Chief Officer | ||
| Klaus Moosmayer, Risk Ethics | ||
| Karen Hale, Chief Officer | ||
| Vasant Narasimhan, Chief Officer | ||
| Harry Kirsch, Chief Officer |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 194.1 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.40 X | |||
| Price To Book | 3.25 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.